Global Astatine-211 Market Growth 2025-2031

The global Astatine-211 market size is predicted to grow from US$ 7.8 million in 2025 to US$ 56.4 million in 2031; it is expected to grow at a CAGR of 39.2% from 2025 to 2031.

Astatine-211 is an isotope of the chemical element astatine (symbol: At) with extremely high radioactivity. The half-life of astatine-211 is 7.2 hours, which is a relatively long-lived astatine isotope.

Astatine-211 is an alpha particle emitter that continuously releases alpha particles consisting of two protons and two neutrons. The chemical properties of astatine are similar to those of other halogens, such as iodine, but the radioactivity of astatine-211 greatly limits the study of its chemical properties.

It can be used to form chemical bonds with metal organic derivatives (such as tin) or carborane precursors, combined with molecular carriers targeting malignant tumor cell groups, to prepare alpha nuclide targeted therapeutic drugs.

Global key players of Astatine-211 include:

• Ionetix
• NIDC (DOE IP)
• Alpha Fusion Inc
• RIKEN

This report also analyzes the strategies of leading global companies with a focus on Astatine-211 portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Astatine-211 market.

Key Questions Addressed in this Report:

1. What is the 10-year outlook for the global Astatine-211 market?
2. What factors are driving Astatine-211 market growth, globally and by region?
3. Which technologies are poised for the fastest growth by market and region?
4. How do Astatine-211 market opportunities vary by end market size?
5. How does Astatine-211 break out by Type, by Application?